Table 1.
Baseline information of human immune deficiency virus-infected male patients (n = 61)
|
Viable
|
Total (n = 61)
|
NGT (n = 50)
|
||
|
mean ± SD or case (%)
|
Range
|
mean ± SD or case (%)
|
Range
|
|
| Age (yr) | 32.05 ± 8.38 | 20-58 | 31.93 ± 8.59 | 20-60 |
| Infection duration (mo) | 11.16 ± 1.19 | 1-86 | 11.16 ± 1.19 | 1-86 |
| T lymphocyte subsets | ||||
| CD3+ (cells/μL) | 1433.98 ± 595.35 | 470-3074 | 1489.7 ± 603.75 | 561-3202 |
| CD3+CD4+ (cells/μL) | 313.87 ± 118.473 | 54-499 | 324.74 ± 150.37 | 10-833 |
| CD3+CD4+% (%) | 19.78 ± 6.83 | 1.4-43.4 | 20.46 ± 8.25 | 1.4-56.8 |
| CD3+CD8+ (cells/μL) | 1119.70 ± 605.0 | 360-2456 | 1100.70 ± 498.72 | 440-2456 |
| CD3+CD8+% (%) | 69.97 ± 13.80 | 36.1-97.2 | 69.31 ± 14.72 | 35.8-97.2 |
| 1Virus load of HIVRNA | 41772.77 ± 10.38 | 895.0-505987.0 | 91126.14 ± 2.64 | 895-970103 |
| Glycose metabolic parameters | ||||
| FPG (mmol/L) | 5.50 ± 0.508 | 3.90-6.53 | 5.39 ± 0.40 | 3.9-6.0 |
| HbA1c (%) | 5.35 ± 0.34 | 4.5-6.2 | 5.25 ± 0.37 | 4.1-6.2 |
| FINS (mIU/L) | 4.55 ± 3.03 | 0.5-11.09 | 2.39 ± 1.16 | 0.5-10.24 |
| HOMA-IR(mIU × mmol/L2) | 1.30 ± 0.84 | 0.81-2.31 | 1.21 ± 0.17 | 0.81-1.74 |
| HOMA-β (mIU/mmol) | 52.37 ± 36.25 | 14.8-182.46 | 64.10 ± 8.44 | 30.8-182.46 |
1
Refers to logarithmic transformation before statistical analysis for nonnormally distributed data. FPG: Fasting plasma glucose; HbA1c: Glycosylated hemoglobin; FINS: Fasting insulin; HOMA-IR: Homeostasis model assessment of insulin resistance; HOMA-β: Homeostasis model assessment of β cells; NGT: Normal glucose tolerance; HIVRNA: Human immune deficiency virus viral nucleic acid.